BioWorld

Nov. 23, 2009

BioCryst $49M Public Offering Cashes in on Stock Momentum

BioCryst Pharmaceuticals Inc. priced a $49 million public offering, cashing in on the 593 percent gain its shares have posted so far this year thanks to progress with flu drug peramivir. (BioWorld Today) Read More

Lawmakers Suspect 'Back-door' Move to Recoup Drug Price Cuts

Novavax $21M Stock Sale Would Fund U.S. Filing for VLP Vaccine

In Today's 'Bench Press': Tech Transfer Impact

Corrections & Clarifications

Other News To Note

Clinic Roundup

Appointments And Advancements

Bench Press

Today's news in brief

BioWorld

BioWorld briefs for July 24, 2026.

4D Nucleome opens new wave of gene regulation research, discovery

BioWorld

After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...

Other news to note for July 22, 2026

BioWorld

Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Akari, Ashlins, Azurity, Eli Lilly, Engitix, Forge Biologics,...

GSK’s newly acquired Jideytro wins FDA nod in NSCLC

BioWorld

About a week after closing its $10.6 billion acquisition of Nuvalent Inc., GSK plc has reaped the first reward, announcing U.S. FDA approval of zidesamtinib in...

Korea targets generics, innovation in drug pricing overhaul

BioWorld

South Korea is moving ahead with its biggest reform of drug review and pricing in more than a decade, reflecting a wider shift across Asian markets to reward...